Patent Covers Use of Plasma Gelsolin to Treat Multiple Sclerosis and to Diagnose Neurologic Diseases

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today that broad US patent protection for plasma gelsolin to treat Multiple Sclerosis (MS) and to diagnosis neurological disease. MS affects approximately 400,000 people in the US and 2.5 million worldwide and has enormous unmet need, despite recent product entries. In the US, prevalence estimates are approximately 90 per 100,000 population. MS symptoms can start anywhere between 10 and 80 years of age, but onset is usually between 20 and 40 years, with a mean of 32 years. According to a global study conducted by the World Health Organization, Neurological disorders are responsible for 8 out of 10 disorders in the 3 highest disability classes.